Amphastar Pharmaceuticals (AMPH) FY2016 results: revenue $255 million, up 1.4% on the year
Amphastar Pharmaceuticals, Inc. (AMPH) reported revenue of $255 million for fiscal 2016, the year ended 31 December 2016, up 1.4% on the year before. Net income was $10 million, and diluted earnings per share $0.21. The figures are the company's own, from the 10-K it filed with the SEC on 15 March 2019.
Revenue
$255 million
+1.4% on the year
FY2012FY2016
Operating margin
6.0%
-2.7% a year earlier
FY2012FY2016
Net income
$10 million
FY2012FY2016
Diluted EPS
$0.21
FY2012FY2016
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Revenue
255
252
210
+1.4%
Cost of revenue
151
174
159
-13.3%
Gross profit
104
77.3
51.3
+34.7%
Gross margin
40.8%
30.8%
24.4%
Research and development
41.5
37.3
28.9
+11.4%
Operating income
15.4
-6.9
-18.0
Operating margin
6.0%
-2.7%
-8.5%
Interest expense
1.0
1.0
0.6
+3.7%
Pre-tax income
14.6
-10.4
-18.1
Income tax
4.8
-7.6
-7.4
Effective tax rate
32.9%
n/a
n/a
Net income
9.8
-2.8
-10.7
Net margin
3.8%
-1.1%
-5.1%
Diluted EPS
$0.21
-$0.06
-$0.25
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Operating cash flow
38.6
10.7
21.1
+261.0%
Capital expenditure
21.4
16.0
20.5
+33.7%
Free cash flow
17.2
-5.3
0.6
Free cash flow margin
6.7%
-2.1%
0.3%
Cash from investing
-39.5
-16.9
n/a
Cash from financing
7.1
2.2
n/a
+219.2%
Depreciation and amortisation
14.7
13.3
14.4
+10.8%
Share-based compensation
15.1
12.8
9.3
+18.0%
Buybacks
9.9
9.9
0.3
+0.4%
Diluted shares, weighted
48m
45m
42m
+5.7%
Shares outstanding at period end
46m
45m
45m
+2.3%
Balance sheet
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Shareholders' equity
329
296
282
+11.4%
Debt
36.0
40.3
42.7
-10.6%
Other liabilities
62.5
54.3
64.8
+14.9%
Total liabilities and equity
428
390
389
+9.6%
Fixed assets
153
142
138
+7.6%
Goodwill
4.0
3.7
4.5
+6.7%
Intangible assets
17.1
7.0
8.9
+146.1%
Investments
0.5
n/a
n/a
Cash and equivalents
72.4
66.1
67.8
+9.5%
Receivables
26.8
33.2
22.9
-19.4%
Inventory
79.8
70.7
82.3
+12.9%
Other assets
74.3
67.3
64.7
+10.4%
Total assets
428
390
389
+9.6%
10-K for the year ended 31 December 2016, filed 15 March 2019: the filing.